COLUMBIA, Md., July 27 /PRNewswire-FirstCall/ -- Martek
Biosciences Corporation (Nasdaq: MATK) announced today that it will
be presenting at the Canaccord Genuity 30th Annual Growth
Conference scheduled to take place August
10-12, 2010 in Boston, MA.
Steve Dubin, Chief Executive Officer, and Peter L. Buzy, Chief Financial Officer, are
scheduled to present on August 11 at
11:30 a.m. Eastern Time.
A live audio webcast of Martek's presentation can be accessed
at: http://www.wsw.com/webcast/canaccord2/matk/
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the
innovation, development, production and sales of high-value
products from microbial sources that promote health and wellness
through nutrition. The company's technology platform consists of
its core expertise, broad experience and proprietary technology in
areas such as microbial biology, algal genomics, fermentation and
oil processing. This technology platform has resulted in Martek's
development of a number of products including the company's
flagship product, life'sDHA(TM), a sustainable and vegetarian
source of algal DHA (docosahexaenoic acid) important for brain,
heart and eye health throughout life for use in infant formula,
pregnancy and nursing products, foods and beverages and dietary
supplements. The company also produces life'sARA(TM) (arachidonic
acid), an omega-6 fatty acid, for use in infant formula and
growing-up milks. Martek's subsidiary, Amerifit Brands, develops,
markets and distributes branded consumer health and wellness
products and holds leading brand positions in all of its key
product categories. Amerifit products are sold in most major mass,
club, drug, grocery and specialty stores and include:
Culturelle(R), a leading probiotic supplement; AZO, the leading OTC
brand addressing symptom relief, detection and prevention of
urinary tract infections; and ESTROVEN(R), the leading all-natural
nutritional supplement brand addressing the symptoms of menopause.
Martek currently has a number of nutritional health and wellness
products under development that it plans to commercialize and
distribute through Amerifit's distribution channels.
Martek's technology platform has also made it a sought-after
partner on a range of groundbreaking projects in process, including
the development of microbially-derived biofuels and the development
of DHA-containing oilseeds. For more information on Martek
Biosciences, visit http://www.martek.com/. For a complete list of
life'sDHA and life'sARA products, visit http://www.lifesdha.com/.
For more information about Amerifit Brands, visit
www.amerifit.com.
Sections of this release contain forward-looking statements.
These statements are based upon numerous assumptions which Martek
cannot control and involve risks and uncertainties that could cause
actual results to differ. These statements should be understood in
light of the risk factors set forth in the company's filings with
the Securities and Exchange Commission, including, but not limited
to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form
10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Contact:
|
Kyle Stults
|
|
|
Investor Relations
|
|
|
(410) 740-0081
|
|
|
|
SOURCE Martek Biosciences Corporation